3:11-22.Raponi M, et al.. Curr Opin Pharmacol 8:1-6, 2008.Tigue CC et al. The value of innovation
nih.gov/ftrs/pick?collect=ahcpr&dbName=0&cc=1&t=880247592AHCPR Home Page: http://www.ahcpr.gov
特异性抗体药物,也是全球首个获批的PD-1/CTLA-4 免疫双抗,具有里程碑式的意义!中国自主研发抗癌药物崛起,从此国内病友也能接收到领先全球的抗癌新药治疗!来源:康方生物官网免疫治疗被誉为攻克癌症
A:link { FONT-SIZE: 10pt; COLOR: #004080; FONT-FAMILY: "=CB=CE=CC=E5", "serif"; = TEXT-DECORATION